Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, describes the main challenges to identifying, measuring, and reducing use of low-value care and the granular data needed to solve these challenges.
Granular data at the level of a health system all the way down to the individual physician are required to improve low-value care measures, said Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare
Transcript:
What are the main challenges to identifying, measuring, and reducing the use of low-value care?
Low-value care is fairly easy to identify and measure. The care can either be in administrative waste—things like billing collection, prior authorization—but more importantly, it's in care delivery. It's care that doesn't improve health outcomes and care that doesn't improve quality of life. So at it’s best, it's wasted, and very often it's harmful. Reducing it, though, is the challenge, and that's the hardest part. To reduce low-value care, I believe, requires a change in our reimbursement model. As long as we continue fee-for-service reimbursement, the incentives will not be aligned to reduce low-value and wasted care.
What data needs to be collected for this?
I think most importantly, the data that is required for improvement in low-value care measures is granular data at the level of a health system, and then a physician group, and then a physician practice, and all the way down to the individual physician. And importantly, I think the data needs to be transparent. It has to be shared with a physician, with their colleagues. They have to have metrics that are comparable across states and across the US. And once we get to the point where everybody is comfortable transparently sharing granular data, that is a very potent change agent and it begins to drive care transformation.
Real-World Data Demonstrate Efficacy of Beti-Cel Gene Therapy
November 28th 2024Investigators said patients experienced adverse effects in line with those expected for myeloablative conditioning with busulfan following treatment with betibeglogene autotemcel (beti-cel; Zynteglo; bluebird bio).
Read More
Expert Insights on How Utilization Management Drives Physician Burnout
November 26th 2024On this episode of Managed Care Cast, we speak with the author of a study published in the November 2024 issue of The American Journal of Managed Care® to explore the link between utilization management and physician burnout.
Listen
US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment
November 27th 2024While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.
Read More